Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 280.00
Bid: 276.00
Ask: 278.00
Change: -6.00 (-2.10%)
Spread: 2.00 (0.725%)
Open: 280.00
High: 280.00
Low: 276.00
Prev. Close: 286.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TOP NEWS: Retailer ASOS now to be seen on London Main Market

Thu, 13th Jan 2022 09:10

(Alliance News) - Online fashion retailer ASOS on Thursday revealed plans to move to the London Main Market, saying it has outgrown AIM after 20 years, most of that time as its biggest listing.

ASOS, which stands for "as seen on screen", long dominated the junior market, though its current market capitalisation of GBP2.42 billion places it fifth in size on AIM. Currently the largest stock traded on AIM is Hutchmed (China) Ltd with a GBP4.18 billion market cap, followed by Abcam PLC and Fevertree Drinks PLC. The move would also put ASOS in contention to join the FTSE 250 index.

ASOS shares were up 8.2% at 2,443.00 pence in London on Thursday morning.

"ASOS directors believe that given ASOS's size and scale, now is the appropriate time to move from AIM to a premium Main Market listing," the company said, explaining it thinks the move will raise its corporate profile and recognition, and increase investment in its shares by global institutions.

ASOS said it will move its listing by the end of February. JP Morgan will act as sponsor for the Main Market admission, which won't involve any fund raise.

In conjunction with the shift, ASOS has hired Patrick Kennedy as senior independent director. Kennedy, the former chief executive of Irish betting firm Paddy Power - now Flutter Entertainment PLC - is the chair of Bank of Ireland Group PLC. He holds 23,000 ASOS shares, which are worth about GBP560,000.

ASOS also provided a trading update for the last four months of 2021.

Total revenue rose by 2.1% to GBP1.39 billion from GBP1.36 billion a year before. In constant currency, the increase was 5%. UK sales rose by 13%, while EU sales rose by 2% and US sales by 11%, both at constant currency. However, Rest of World sales fell by 15% at constant currency and by 20% at actual rates.

ASOS said that while UK sales benefited from Britons going out once again, the fourth wave of Covid-19 limited this in Europe. In the US, ASOS note significant port congestion and supply chain disruption, restricting its ability to fulfil orders. ROW sales also were hurt by "the continued impact of extended delivery propositions".

Gross margin narrowed by 400 basis points to 43.0%, as expected, ASOS said, due to clearance activity. The product returns rate has normalised in line with expectations.

ASOS said that, despite uncertainty related to the Omicron variant of Covid-19, its full-year guidance remains unchanged at 10% to 15% revenue growth and adjusted pretax profit of GBP110 million to GBP140 million. In the financial year that ended August 31, 2021, ASOS recorded GBP3.91 billion in revenue, up from GBP3.26 billion the year before, with adjusted pretax profit of GBP193.6 million, up from GBP142.1 million.

"Our listing on AIM for the past 20 years has been an important part of ASOS's development, but the time is now right to move to the Main Market as we focus on delivering our medium-term guidance and longer-term growth ambitions," said Chief Operating Officer Mat Dunn.

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
4 Sep 2020 14:13

Hutchison Chi-Med begins latest trial of fruquintinib

(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, said on Friday that it has initiated 'FRESCO-2' - a phase 3 registration study of 'fruquintinib' for the treatment of patients with metastatic colorectal cancer (CRC) in the US, Europe and Japan.

Read more
3 Sep 2020 21:27

IN BRIEF: Hutchison China Initiates Phase II Trial Of HMPL-453

IN BRIEF: Hutchison China Initiates Phase II Trial Of HMPL-453

Read more
10 Aug 2020 11:04

IN BRIEF: Hutchison Chi-Med Plans Surufatnib Marketing Application

IN BRIEF: Hutchison Chi-Med Plans Surufatnib Marketing Application

Read more
30 Jul 2020 17:56

IN BRIEF: Hutchison China Interim Loss Widens Despite Revenue Growth

IN BRIEF: Hutchison China Interim Loss Widens Despite Revenue Growth

Read more
28 Jul 2020 19:48

IN BRIEF: Hutchison China Amends License Agreement With Eli Lilly

IN BRIEF: Hutchison China Amends License Agreement With Eli Lilly

Read more
24 Jul 2020 15:45

Hutchison Chi-Med begins phase 1 study of 'HMPL-306'

(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, has initiated a phase 1 study of 'HMPL-306', it announced on Friday, in patients with hematological malignancies in China.

Read more
24 Jul 2020 14:33

Chi-Med Trials Dual Inhibitor For Hematological Cancer

Chi-Med Trials Dual Inhibitor For Hematological Cancer

Read more
23 Jul 2020 16:03

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
23 Jul 2020 16:02

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
25 Jun 2020 15:08

Hutchison China Gets USD100 Million From US Private Equity Firm

Hutchison China Gets USD100 Million From US Private Equity Firm

Read more
18 Jun 2020 16:46

IN BRIEF: Hutchison China Gets US FDA Fast Track For Cancer Drug

IN BRIEF: Hutchison China Gets US FDA Fast Track For Cancer Drug

Read more
18 Jun 2020 09:18

Hutchison Chi-Med gets FDA fast track approval for fruquintinib

(Sharecast News) - Hutchison China MediTech, trading as 'Chi-Med', announced on Thursday that the US Food and Drug Administration (FDA) has granted 'fast track designation' for the development of 'fruquintinib'.

Read more
9 Jun 2020 14:06

Hutchison Chi-Med venture to surrender unused land in Guangzhou

(Sharecast News) - Hutchison China MediTech, trading as 'Chi-Med', announced on Tuesday that Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company (HBYS) - its 50-50 joint venture with Guangzhou Baiyunshan Pharmaceutical Holdings - has agreed the planned return of its remaining 34 years land-use rights on its 30,000 square metre unused site in Tong He Town with the Guangzhou government.

Read more
9 Jun 2020 13:25

UK TRADING UPDATE SUMMARY: Venture Life Sees Order Boost For Sanitiser

UK TRADING UPDATE SUMMARY: Venture Life Sees Order Boost For Sanitiser

Read more
4 Jun 2020 13:19

UK TRADING UPDATE SUMMARY: Open Orphan Launches Covid Testing Service

UK TRADING UPDATE SUMMARY: Open Orphan Launches Covid Testing Service

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.